Prof. Xu’s research is centered on the design and synthesis of novel drug candidates, structural modification of natural products, and the development of innovative therapeutic modalities such as PROTAC (proteolysis-targeting chimeras) and HyT (hydrophobic tagging) degraders. Her work particularly addresses therapeutic areas like hypertension, cancer, and Alzheimer’s disease. Her current research projects funded by the National Natural Science Foundation of China focus on degradation-based therapeutic strategies and prodrug design using bioorthogonal chemistry.
Prof. Dr. Jinyi Xu | Medicinal Chemistry | Best Researcher Award
Prof. Jinyi Xu is a professor of Medicinal Chemistry at China Pharmaceutical University. She earned her B.S. and Ph.D. from the same university and completed a postdoctoral fellowship at Kinki University, Japan. Her research focuses on the design and synthesis of novel drug candidates, natural product modification, and targeted protein degradation strategies like PROTACs and HyT. She has led over 10 major research projects, holds more than 40 patents, and has published over 200 peer-reviewed papers. Prof. Xu is also an Associate Editor of Bioorganic Chemistry and an active member of several national pharmaceutical committees.
-
Novel agents derived from natural product β-elemene: A second round of design and synthesis to enhance antitumor properties
Authors: Liu Zhouyan, Li Tong, Gu Chenglei, Xu Jingyi, Chen Jichao
Journal: Bioorganic and Medicinal Chemistry, 2025 -
In Vivo Self-Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy
Authors: Xie Shaowen, Zhu Jingjie, Peng Yihan, Su Zhigui, Xu Shengtao
Journal: Angewandte Chemie International Edition, 2025 -
Discovery of hematopoietic progenitor kinase 1 inhibitors using machine learning-based screening and free energy perturbation
Authors: Feng Dazhi, Liu Bo, Chen Zhiwei, Ai Jing, Zhang Hefeng
Journal: Journal of Biomolecular Structure and Dynamics, 2025 -
Design, synthesis, and biological evaluation of novel HPK1 inhibitors possessing 3-cyano-quinoline moiety
Authors: Chen Long, Zhang Baixue, Zhou Pijun, Yao Hong, Xu Jingyi
Journal: Bioorganic Chemistry, 2024 -
Palladium-Mediated Bioorthogonal System for Prodrug Activation of N-Benzylbenzamide-Containing Tubulin Polymerization Inhibitors for the Treatment of Solid Tumors
Authors: Li Jinlong, Zhang Tong, Wu Di, Xu Jingyi, Xu Shengtao
Journal: Journal of Medicinal Chemistry, 2024
hi
Jinyi Xu | Medicinal Chemistry | Best Researcher Award